ARTICLE | Deals
A deal for Grail could be Illumina’s next shot at diversifying
September 16, 2020 11:26 PM UTC
Nine months after abandoning its bid to acquire PacBio, tools company Illumina is in talks to bring its spinout Grail back into the fold, according to a report.
Doing so wouldn’t come cheap. The offer would likely come at a premium to the $6 billion valuation Grail Inc. garnered from its series D round in May, according to a Bloomberg article that cited undisclosed sources...